DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

April 2, 2025

Study Completion Date

April 2, 2025

Conditions
Diabetes (Insulin-requiring, Type 1 or Type 2)Pancreatogenic Diabetes Mellitus
Interventions
DEVICE

Smart Insulin Pen

During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.

DEVICE

Injection of bolus insulin via conventional therapy using insulin pen

During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.

Trial Locations (1)

135710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

G2e Co., Ltd

INDUSTRY

NCT06406439 - DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients | Biotech Hunter | Biotech Hunter